Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label single-arm study of intravenous human immunoglobulin in adults with primary immune thrombocytopenia
ChiCTR2300069388Phase 3Completed
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Apr 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of immune serum globulin in immune thrombocytopenia (ITP), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Total response rate within 7 days after treatment initiation. Started Apr 2020; status: completed.
02
Drugs
immune serum globulin
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on ChiCTR2300069388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300069388.